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Background: Slow heart rate recovery (HRR) after exercise is associated with autonomic 
dysfunction and increased mortality. What HRR criterion at 1-minute after a 6-minute walk 
test (6MWT) best defines pulmonary impairment?.
Study Design and Methods: A total of 5008 phase 2 COPDGene (NCT00608764) 
participants with smoking history were included. A total of 2127 had COPD and, of these, 
385 were followed-up 5-years later. Lung surgery, transplant, bronchiectasis, atrial fibrilla-
tion, heart failure and pacemakers were exclusionary. HR was measured from pulse oximetry 
at end-walk and after 1-min seated recovery. A receiver operator characteristic (ROC) 
identified optimal HRR cut-off. Generalized linear regression determined HRR association 
with spirometry, chest CT, symptoms and exacerbations.
Results: HRR after 6MWT (bt/min) was categorized in quintiles: ≤5 (23.0% of participants), 6– 
10 (20.7%), 11–15 (18.9%), 16–22 (18.5%) and ≥23 (18.9%). Compared to HRR≤5, HRR≥11 
was associated with (p<0.001): lower pre-walk HR and 1-min post HR; greater end-walk HR; 
greater 6MWD; greater FEV1%pred; lower airway wall area and wall thickness. HRR was 
positively associated with FEV1%pred and negatively associated with airway wall thickness. An 
optimal HRR ≤10 bt/min yielded an area under the ROC curve of 0.62 (95% CI 0.58–0.66) for 
identifying FEV1<30%pred. HRR≥11 bt/min was the lowest HRR associated with consistently 
less impairment in 6MWT, spirometry and CT variables. In COPD, HRR≤10 bt/min was 
associated with (p<0.001): ≥2 exacerbations in the previous year (OR=1.76[1.33–2.34]); 
CAT≥10 (OR=1.42[1.18–1.71]); mMRC≥2 (OR=1.42[1.19–1.69]); GOLD 4 (OR=1.98[1.44– 
2.73]) and GOLD D (OR=1.51[1.18–1.95]). HRR≤10 bt/min was predicted COPD exacerbations 
at 5-year follow-up (RR=1.83[1.07–3.12], P=0.027).
Conclusion: HRR≤10 bt/min after 6MWT in COPD is associated with more severe expiratory 
flow limitation, airway wall thickening, worse dyspnoea and quality of life, and future exacer-
bations, suggesting that an abnormal HRR≤10 bt/min after a 6MWT may be used in 
a comprehensive assessment in COPD for risk of severity, symptoms and future exacerbations.
Keywords: autonomic dysfunction, chest computed tomography, COPD exacerbation, 
exercise, spirometry
Background
Chronic obstructive pulmonary disease (COPD) is associated with autonomic 
dysfunction1,2 that predicts increased mortality.3,4 Heart rate recovery (HRR) after 
exercise is an easily-acquired measure of autonomic dysfunction.5 Abnormal HRR 
after maximal exercise, such as a cardiopulmonary exercise test (CPET), predicts 
overall mortality in various populations,5–7 and associates with pulmonary function 
abnormalities.8 In addition, in COPD, prevalence of impaired HRR increases with 
greater GOLD-defined severity of expiratory flow limitation.9
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The 6-minute walk test (6MWT) is a simple test of 
functional performance that is used widely in COPD 
patient assessment. Six-minute walk distance (6MWD) 
associates negatively with COPD hospitalizations, exacer-
bations and mortality10 and also predicts survival in 
patients with heart failure,11 idiopathic pulmonary 
fibrosis12 and pulmonary hypertension.13 Previous studies 
used values of ≤12, ≤13, ≤14 or ≤16 bt/min as criterion to 
identify abnormal HRR in cardiovascular disease 
patients,5,12,14 but a criterion to define a suitable HRR cut- 
off after 6MWT in COPD is not well established.
A previous study indicated that HRR≤14 bt/min after 
a symptom-limited incremental exercise test strongly pre-
dicted mortality in 147 COPD patients.7 Rodriguez et al 
found, in 101 COPD patients, that HRR≤14 bt/min after 
6MWT associated with higher exacerbation risk during the 
subsequent 12 months.15 Criteria defining normality in 
these studies were based on small sample sizes (<150 
COPD patients)7,15 and were not associated with pulmon-
ary function or symptoms.15 In COPD, exercise may be 
limited by respiratory symptoms prior to reaching cardio-
vascular limits, often with substantial heart rate reserve; 
therefore, COPD patients with more severe obstruction or 
greater symptom burden may exhibit lower HRR follow-
ing a 6MWT. Furthermore, autonomic function may be 
associated with changes that affect vagal afferent innerva-
tion of the respiratory tract16,17 reflected in anatomic chest 
CT variables. Establishing a criterion HRR following 
6MWT in COPD that is associated with lung function, 
dyspnoea and quality of life and future exacerbations (as 
opposed to cut-offs established in other disease states or 
testing modalities) has the potential to provide insight into 
health status and guide management. We therefore aimed 
to identify an HRR abnormality criterion after 6MWT that 
associated independently with COPD, COPD severity, 
symptoms, and predicted future exacerbations. To achieve 
this, we analysed data from the longitudinal cohort study, 
the Genetic Epidemiology of COPD (COPDGene).
Methods
Study Design and Population
This was a retrospective analysis of COPDGene18 
(NCT00608764) participants at 5 years (phase 2; 2012– 
2017) and 10 years (Phase 3; 2017–2019) after their initial 
study visit. The 5-year visit was the first visit at which 
HRR was recorded. COPDGene enrolled current and for-
mer smokers with ≥10 pack-years smoking history and 
never smokers. Participants were either Non-Hispanic 
White or African American and aged 45–90 years at 
their 5-year visit. A detailed description of the study 
design and inclusion/exclusion criteria is available.18 
Those with complete 6MWT and lung function data were 
included in the analysis and those with lung surgery, 
transplant, bronchiectasis, atrial fibrillation, heart failure, 
and pacemakers were excluded. Participants underwent 
6MWT, post-bronchodilator spirometry, quantitative com-
puted tomography (CT), and questionnaires to assess 
symptoms and medical history. The COPDGene protocol 
was approved by institutional review boards at 21 partici-
pating centres (see online supplement) and conducted in 
accordance with the Declaration of Helsinki. Written 
informed consent was obtained from all participants.
Measurements
6MWT was performed at all sites according to ATS 
guidelines19 and as described in the COPDGene manual 
of procedures. Heart rate and SpO2 were measured using 
a pulse oximeter after 10 minutes of seated rest prior to the 
walk, immediately at walk’s end, and 1-minute after the 
end of the walk. At the end of the walk, participants were 
seated as quickly but as safely as possible. HRR (indepen-
dent variable) was defined as the difference in HR between 
end-walk and 1-min recovery. HRR grades were identified 
according to quintiles of HRR: HRR≤5 bt/min, 6–10 bt/ 
min, 11–15 bt/min, 16–22 bt/min and HRR ≥23 bt/min.
Exposures included smoking history, exacerbation his-
tory, and medication use. Outcome variables included the 
scores of the modified Medical Research Council dys-
pnoea questionnaire (mMRC) and COPD assessment test 
(CAT). Exacerbation frequency during the year prior to the 
5-year or 10-year follow-up visits, with exacerbation 
defined as acute worsening of COPD symptoms that 
resulted either in prescription of a course of antibiotics 
or oral corticosteroids, or in hospitalization (ie, moderate 
or severe exacerbations).20 Frequent exacerbations were 
defined as ≥2 exacerbations in the previous year.20,21 
Outcomes also included COPD severity, assessed by 
GOLD spirometric stage, and COPD Group by assessment 
of symptoms and risk of exacerbations based on the 2020 
GOLD guidelines, eg GOLD group D were those with 
mMRC ≥2 or CAT ≥10 and exacerbation frequency ≥2 
in the previous year.20
Spirometry was performed using an EasyOne® 
Spirometer (ndd, Zurich, Switzerland) before and after 
administration of a short-acting β2-agonist (albuterol) 
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according to ATS/ERS recommendations.22 Spirometry 
studies were reviewed centrally by COPDGene to ensure 
multicentre quality control.18 The greatest combined FEV1 
and FVC measurements of three acceptable efforts was 
reported. Lung diffusing capacity for carbon monoxide 
(DLCO) was measured by using the EasyOne Pro system 
(ndd Medical Technologies, Inc.) in accordance with 
European Respiratory Society/American Thoracic Society 
standards for measurement of single-breath carbon mon-
oxide uptake in the lung.23 DLCO percent predicted values 
were calculated by using Global Lung Initiative reference 
equations,24 with DLCO values adjusted for haemoglobin 
and altitude.
Exploratory outcomes included CT scans variables. CT 
scan at phase 2 COPDGene were performed at full inspira-
tion (200 mAs), and at the end of normal expiration (50 
mAs).18 Airway wall thickening was assessed by segmen-
tal airway wall thickness (AWT) calculated as average 
values in six segmental bronchi, segmental wall area per-
centage (WA%=[outer bronchus area-airway luminal 
area]/outer bronchus area×100) obtained at the same sites 
as used for airway wall thickness, and the square root of 
wall area of a 10-mm perimeter airway (Pi10).25–27 
Emphysema percentage was defined as percentage of 
lung voxels ≤−950 Hounsfield units (HU) on an end- 
inspiratory CT scan, and gas trapping percentage was 
defined as percentage of lung voxels ≤−856 HU on expira-
tory CT.27,28
Statistical Analyses
Data are presented as mean±SD, median (interquartile 
range) or number (percent). Univariate analyses were per-
formed using one-way ANOVA, Kruskal–Wallis tests, 
independent-samples Student’s t or Mann–Whitney test 
for continuous variables and chi-square test or z-test for 
proportions, as appropriate. Associations between HRR or 
HRR quintile (independent variables) and pulmonary func-
tion and quantitative CT (dependent variables) were 
assessed by multivariable generalized linear regression 
models. Emphysema percentage and gas trapping percen-
tage were natural log transformed to account for skewed 
distributions. Estimates of linear trend across increasing 
HRR quintiles were performed by including median of 
each quintile as a continuous variable (providing a P-for- 
trend value). The optimal HRR cut-off point (highest sum 
of sensitivity and specificity) to identify FEV1<30%pred 
was selected using receiver operating characteristic (ROC) 
analysis. Relationships between HRR cut-off (independent 
variable) and exacerbations and symptoms (dependent 
variables) were assessed by logistic regression models. 
At the 5-year visit (phase 2) relationships between HRR 
and exacerbation frequency ≥2 in the previous year, CAT 
≥10 and mMRC ≥2 were assessed. COPD patients with 
available data were followed-up at the 10-year visit 
(phase 3), where the relationship between HRR at phase 
2 and exacerbations in the year prior to phase 3 was 
assessed. Multivariable models were adjusted for race, 
sex, age, body mass index (BMI), smoking history, cardi-
ovascular disease (CVD) history and (for CT measures) 
CT scanner type. All statistical analyses were performed 
using SPSS (IBM SPSS V.25.0, Armonk, NY, USA). 
Alpha level was set at P<0.05, with Bonferroni correction 
where needed to account for multiple comparisons. 
Figures were created using GraphPad Software 




10,311 non-Hispanic white and African American partici-
pants were initially enrolled in COPDGene (phase 1). Of 
these, 6758 were followed-up at phase 2 (5-year visit). Of 
those, 1750 were excluded from this analysis (Figure 1): 
876 of these did not conduct 6MWT or spirometry; and 
874 were excluded on the basis of history of other lung 
disease including interstitial lung disease (ILD) and 
bronchiectasis, or history of heart disease including atrial 
fibrillation and heart failure, or previous lung resection or 
being a never-smoker. 5008 participants were included for 
analysis, of whom 2127 (42.5%) had COPD, 627 had 
preserved ratio with impaired spirometry (PRISm), and 
2254 had normal spirometry. 385 of the COPD patients 
with 5.5±0.5 years of follow-up duration were also 
assessed at the 10-year visit of COPDGene. The remaining 
participants had either not yet reached their 10-year visit 
date or were lost to follow-up.
To identify variables associated the HRR across the 
whole cohort, we compared HRR characteristics with the 
reference group of HRR ≤5 bt/min (Table 1). Compared 
with HRR ≤5 bt/min, individuals with 6≤HRR≤10 bt/min 
had greater 6MWD, BMI, end-walk HR and DLCO%pred 
and slightly lower Pi10 from quantitative CT (Table 1). 
However, spirometry, and most other 6MWT- and CT- 
related variables were not statistically different between 
the first 2 quintiles of HRR (Table 1).
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However, participants in the 3rd quintile (11≤HRR≤15 
bt/min) had many variables that were significantly differ-
ent from reference (HRR≤5 bt/min). Those with HRR≥11 
bt/min were older, with greater BMI and 6MWD, lower 
pre-walk HR and 1-min post HR, greater end-walk HR and 
SpO2, less impaired spirometry (FEV1%pred, FEV1/FVC), 
greater DLCO%pred, less gas trapping, Pi10 and airway 
wall thickness. Therefore, 6MWT, spirometry and CT 
variables were significantly less impaired in participants 
at HRR≥11 bt/min compared with those in the first two 
quintiles. Above this quintile, there were few additional 
significant findings: greater pack-years smoking, greater 
pre-walk and end-walk SpO2, greater FVC%pred and 
lower airway wall thickness (at HRR≥16 bt/min), and 
less emphysema (at HRR≥23 bt/min). In ROC analysis, 
an optimal HRR≤10 beat/min yielded an area under the 
curve (AUC) of 0.62 (95% CI 0.58–0.66) for identifying 
FEV1<30%pred. This cut-off corresponded to a sensitivity 
of 62% and specificity of 58%. Overall, in smokers with 
and without COPD, HRR≥11 bt/min was the lowest HRR 
associated with consistently less impairment in 6MWT, 
spirometry and CT variables.
Spirometry, Chest CT and HRR
Associations between measures of pulmonary function and 
HRR in the whole cohort were further assessed by multi-
variable generalized linear regression models, adjusted for 
age, sex, race, BMI, smoking status and cardiovascular dis-
ease history. When modelled as a continuous variable, HRR 
was independently associated with spirometry (Table 2). In 
categorical analyses, compared with HRR≤5 bt/min, pul-
monary function variables (FEV1%pred, FVC%pred, FEV1 
/FVC and DLCO%pred) were greater (each P<0.001) when 





28 history of other lung disease including 
ILD and bronchiectasis
300 history of  heart disease including atrial 
fibrillation and heart failure
131 previous lung resection
415 never smokers
5,008 participants at phase 2 COPDGene
2,127 with COPD
627 with PRISm















2,254 with normal spirometry
1,742 with COPD but without 10-year follow-
up data
Figure 1 Study design. 
Abbreviation: PRISm, Preserved Ratio Impaired Spirometry defined as FEV1/FVC≥70% but FEV1<80%.
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HRR≥11 bt/min, and increased progressively across HRR 
quintiles above this level (each P for trend <0.001) (Table 2).
To identify the locus of these associations we per-
formed a sub-group analysis of HRR in COPD, PRISm 
and normal spirometry. We found that the associations 
were driven largely by the COPD group, because there 
were no consistent associations between HRR quintiles 
and pulmonary function variables in PRISm and normal 
spirometry groups, assessed separately (Table 3). Only 
FVC%pred was weakly associated (β = 0.043, 95% CI = 
0.008 to 0.079) with HRR as a continuous variable in 
normal spirometry smokers. In the COPD sub-group, how-
ever, all pulmonary function variables were significantly 
associated with HRR considered as a continuous variable, 
or as a trend across quintiles (P<0.05) (Table 3).
We also aimed to explore associations between pul-
monary morphology measured by quantitative CT, and 
HRR in the whole cohort. Multivariable generalized lin-
ear regression models were adjusted for age, sex, race, 
BMI, smoking status, cardiovascular disease history, and 
CT scanner type. Using HRR as a continuous variable, 
HRR was independently negatively associated with wall 
area percentage, airway wall thickness and Pi10 (each 
P<0.001) but not with emphysema or gas trapping 
(Table 2). This association was also observed in catego-
rical analyses, with wall area percentage, airway wall 
thickness and Pi10 being consistently less impaired at 
HRR≥11 bt/min compared with reference (HRR≤5 bt/ 
min; each P<0.05; Table 2). There was progressive 
decrease in wall area percentage, airway wall thickness 
and Pi10 with increase in HRR quintile (each P for trend 
<0.001), but not with emphysema or gas trapping (each 
P for trend >0.124; Table 2). These findings were again 
corroborated in subgroup analysis (Table 3) where, in 
COPD patients, wall area percentage, airway wall thick-
ness and Pi10, but not emphysema or gas trapping, were 
associated with HRR when HRR was considered as 
continuous or as categorical variable with HRR≥6 bt/ 
min. Wall area percentage and airway wall thickness 
were significantly negatively associated with HRR as 
continuous variable in PRISm subjects, however these 
associations were extremely weak (β < −0.022; Table 3).
COPD Symptoms, Severity and HRR
Finding significant associations between HRR and ana-
tomic and functional variables in the COPD sub-group, 
we then assessed associations with COPD symptoms. 
Multivariable logistic regression models were adjusted 
for age, sex, race, BMI, smoking status and cardiovascular 
disease history. When HRR was modelled as a continuous 
variable, HRR was independently associated with severe 
symptoms and exacerbation frequency ≥2 (Table 4). In 
categorical analyses, compared with HRR≤5 bt/min, odds 
ratios (ORs) of severe symptoms were decreased (each 
P<0.05) when HRR≥11 bt/min, and decreased progres-
sively across HRR quintiles above this level (each P for 
trend <0.001) (Table 4).
In univariable and multivariable analyses, significant 
differences among 6MWT, pulmonary function and CT 
variables in COPD patients were first observed at 
HRR≥11 bt/min. We therefore explored the association 
between HRR≤10 bt/min and COPD severity. After 
adjusting for age, sex, race, BMI, smoking status and 
cardiovascular disease history, HRR≤10 bt/min was 
independently associated (P<0.001) with: Exacerbation 
frequency ≥2 in the previous year (OR=1.76[1.33– 
2.34]); CAT ≥10 (OR=1.42[1.18–1.71]); and mMRC ≥2 
(OR=1.42[1.19–1.69]) (Figure 2A). Compared to those 
with HRR≥11 bt/min, COPD patients with HRR≤10 bt/ 
min had 1.97 times the risk of very severe obstruction 
(OR for GOLD 4 =1.98[1.44–2.73]) and 1.51 times the 
risk of having worse symptoms combined with ≥2 
exacerbations in the previous year (OR for GOLD 
D=1.51[1.18–1.95]) (Figure 2B).
HRR Predicts Exacerbations at 5-Years
We then assessed the prognostic value of HRR 10≤bt/min 
for future exacerbations. Logistic regression models 
assessed association between HRR≤10 bt/min and exacer-
bations in the year preceding the phase 3 visit in 385 
COPD patients. Risk ratios (RR) of future exacerbations 
predicted by abnormal HRR are presented in Table 5. RR 
was essentially constant in the crude model, and across 5 
models adjusting for a range of variables (Table 5). After 
adjusting for sex, age, BMI, race, smoking status, cardio-
vascular disease history, FEV1%pred, DLCO%pred and 
6MWD, HRR≤10 bt/min was associated with exacerba-
tions risk ratio (RR=1.83[1.07–3.12], P=0.027) (Table 5).
COPD Characteristics Stratified by HRR
Having identified an optimal cut-off of HRR≤10 bt/min 
was associated with airway morphology, disease severity, 
dyspnoea, quality of life, exacerbation frequency and risk 
of future exacerbations in COPD, we compared the char-
acteristics of COPD patients at phase 2 (n=2127) with 
HRR≤10 bt/min and ≥11 bt/min. Compared with COPD 
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patients with HRR≥11 bt/min, those with HRR≤10 bt/min 
had significantly (P<0.01): Worse pulmonary function; 
worse 6MWT physiology (including lower 6MWD, 
greater pre-walk-HR, lower end-walk-HR, and less recov-
ery of SpO2); worse emphysema and airway morphology 
on chest CT; more severe COPD symptoms; greater 
exacerbation frequency; and greater combination of 
inhaled long-acting beta-agonist, inhaled long-acting mus-
carinic antagonist and inhaled corticosteroid use (Table 6).
Discussion
This is the first study to show that HRR≤10 bt/min after 
6MWT in COPD patients was an important cut-off which 
was significantly associated with impaired 6MWT dis-
tance, spirometry and DLCO and CT variables of airway 
morphology. This is also the first study to show that low 
HRR was independently associated with airway wall 
thickening in smokers with or without COPD, suggesting 
airway morphologic changes may influence autonomic 
function. Using HRR≤10 bt/min cut-off, we showed 
increased odds in COPD patients of worse dyspnoea and 
quality of life and increased exacerbation frequency. In 
addition, in a subgroup of 385 COPD patients, we also 
showed that HRR≤10 bt/min was a significant predictor of 
exacerbations during the year preceding the 5 year follow- 
up visit. HRR≤10 bt/min at 1-minute after a 6MWT in 
COPD is, therefore, proposed as an important tool to 
evaluate the clinical manifestation of severe outcomes in 
COPD.
Seshadri et al (2004) were the first to characterize HRR 
in COPD patients. In 627 participants, they found that 
HRR≤12 bt/min after incremental exercise testing in smo-
kers and non-smokers was associated with spirometric 
abnormalities, such as lower FEV1%pred.8 This was cor-
roborated by Gupta et al (2013), who found that COPD 
patients with HRR≤12 bt/min after target-HR-limited or 
symptom-limited incremental cycle ergometry had lower 
FEV1%pred than those with HRR≥13 bt/min, and that 
abnormal HRR increased in frequency together with 
GOLD-defined COPD severity.9 Both studies used the 
HRR≤12 bt/min criterion established by Cole et al 
(1999) who - from a prospective cohort referred for exer-
cise testing - showed that this cut-off associated with 
mortality in cardiovascular disease patients.5 It was sug-
gested that autonomic dysfunction (reflected in elevated 
heart rate, reduced baroreflex sensitivity, reduced heart rate 
variability and/or prolonged QTc interval) would also 
result in low HRR following exercise.29 However, the 
Figure 2 Odds ratio of COPD severity based on abnormal heart rate recovery (HRR≤10 bt/min). Multivariable logistic regression model for patients with COPD (n=2127) 
at baseline, adjusting for age, sex, race, BMI and smoking status. (A) Associations between abnormal HRR and severe symptoms. (B) Associations between abnormal HRR 
and COPD severity grades. 
Abbreviations: HRR, heart rate recovery; CAT, COPD assessment test; mMRC, modified Medical Research Council dyspnoea scale; GOLD, Global Initiative for Chronic 
Obstructive Lung Disease.
Table 5 Risk Ratio (RR) for Exacerbations in the Year Prior to 
5-Year Follow-Up in 385 Patients with COPD Heart Rate 
Recovery (HRR) ≤10 bt/min Compared to Those with HRR 
≥11 bt/min (Reference)
Variable RR 95% CI P value
Crude 1.759 1.121–2.758 0.014
Model 1 1.747 1.111–2.745 0.016
Model 2 1.762 1.118–2.775 0.015
Model 3 1.775 1.126–2.798 0.014
Model 4 1.823 1.148–2.894 0.011
Model 5 1.827 1.071–3.115 0.027
Notes: Logistic regression model for COPD patients followed-up for 5-years 
(n=385). Crude: Single factor for logistic regression. Model 1: Adjusted for sex. 
Model 2: Adjusted for sex, age. Model 3: Adjusted for sex, age, body mass index 
(BMI). Model 4: Adjusted for sex, age, body mass index (BMI), race, smoking status, 
CVD. Model 5: Adjusted for sex, age, body mass index (BMI), race, smoking status, 
CVD, FEV1%pred, DLCO%pred, 6MWD.
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Table 6 Characteristics of Patients with COPD Stratified by a Criterion Heart Rate Recovery (HRR) After 6MWT of 10 bt/min
Variables COPD with Abnormal HRR 
≤10 bt/min (n=1027)
COPD with Normal HRR ≥11 
bt/min (n=1100)
Total (n=2127) P value
Demographics
Age (years) 67.5±8.5 67.5±8.1 67.5±8.3 0.958
Sex, Male, n (%) 570 (28.3%) 602 (26.8%) 1172 (55.1%) 0.720
BMI (kg/m2) 27.6±6.2 28.1±6.1 27.9±6.2 0.069
Race, Non-Hispanic White, n (%) 743 (34.9%) 857 (40.3%) 1600 (75.2%) 0.003
Smoking status, n (%)
Ex-smoker 631 (29.7%) 707 (33.2%) 1338 (62.9%) 0.177
Current smoker 396 (18.6%) 393 (18.5%) 789 (37.1%) 0.177
Smoking (pack-years) 51±26 49±24 50±25 0.107
6-min walk test
6MWD (m) 350.3±118.7 396.6±122.8 374.3±123.0 <0.001
HR pre-walk (bt/min) 76±13 73±12 75±13 <0.001
SpO2 pre-walk (%) 95.0±3.7 95.6±3.1 95.3±3.4 0.001
HR end-walk (bt/min) 91±17 104±17 98±18 <0.001
HR 1-min post (bt/min) 87±16 83±15 85±16 <0.001
SpO2 end-walk (%) 91.9±6.0 92.1±6.0 92.0±6.0 0.531
SpO2 1-min post (%) 94.6±4.6 95.5±3.9 95.1±4.2 <0.001
Pulmonary function
Post-BD FEV1%pred (%) 59.7±22.5 64.1±22.4 62.0±22.6 <0.001
Post-BD FVC%pred (%) 81.9±19.5 85.4±19.8 83.7±19.7 <0.001
Post-BD FEV1/FVC (%) 53.8±12.7 55.5±11.7 54.7±12.3 0.001
DLCO%pred (%) 62.6±22.1 66.1±21.5 64.4±21.9 0.001
Quantitative chest CT
Emphysema (%) 5.9 (1.9–16.6) 5.0 (1.6–14.5) 5.4 (1.7–15.3) 0.008
Gas trapping (%) 31.1 (18.3–51.5) 29.6 (15.8–46.3) 30.4 (16.9–49.2) 0.005
Pi10 (mm) 2.6±0.6 2.5±0.6 2.5±0.6 0.035
WA (%) 53.6±8.3 52.6±8.2 53.1±8.2 0.011
AWT (mm) 1.11±0.24 1.07±0.22 1.09±0.23 0.001
COPD assessment
Exacerbations/year 0 (0–1) 0 (0–0) 0 (0–1) 0.036
Exacerbation frequency ≥2, n (%) 139 (6.5%) 92 (4.3%) 231 (10.9%) <0.001
mMRC 2 (0–3) 1 (0–3) 2 (0–3) <0.001
CAT 15 (8–22) 12 (7–19) 13 (7–20) <0.001
CAT ≥10, n (%) 716 (33.7%) 677 (31.8%) 1393 (65.5%) <0.001
mMRC ≥2, n (%) 569 (26.8%) 514 (24.2%) 1083 (50.9%) <0.001
Medication, n (%)
Non-medication 336 (15.8%) 453 (21.3%) 789 (37.1%) <0.001
LABA use 11 (0.5%) 8 (0.4%) 19 (0.9%) 0.400
LAMA use 99 (4.7%) 88 (4.1%) 187 (8.8%) 0.182
LABA+LAMA use 18 (0.8%) 20 (0.9%) 38 (1.8%) 0.909
ICS+LABA or LAMA use 168 (7.9%) 164 (7.7%) 332 (15.6%) 0.357
LABA+LAMA+ ICS use 206 (9.7%) 177 (8.3%) 383 (18.0%) 0.017
Others 189 (8.9%) 190 (8.9%) 379 (17.8%) 0.496
Note: Data are presented as mean±SD or median (interquartile range), or number (percent). 
Abbreviations: HRR, heart rate recovery; BMI, body mass index; SpO2, oxygen saturation by pulse oximeter; 6MWD, 6-minute-walk distance; BD, bronchodilator; FEV1, 
forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusing capacity of the lungs for carbon monoxide; DLCO%pred, percentage of predicted DLCO, 
adjusted for haemoglobin concentration and altitude; CT, computed tomography; Pi10, square root wall area of a 10-mm perimeter airway; WA%, segmental wall area 
percentage; AWT, segmental airway wall thickness; CAT, COPD assessment test; mMRC, modified Medical Research Council dyspnoea scale; GOLD, Global Initiative for 
Chronic Obstructive Lung Disease; LABA, inhaled long-acting beta-agonist; LAMA, inhaled long-acting muscarinic antagonist; ICS, inhaled corticosteroid.
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HRR≤12 bt/min criterion value may not be suitable after 
6MWT in COPD patients, who commonly reach symptom 
limitation before reaching cardiovascular limitation during 
exercise.30 Lower peak HR during exercise would predis-
pose towards smaller HRR. Indeed, our data show in 
COPD patients stratified on HRR≤10 bt/min (Table 6), 
that pre-walk HR is significantly higher (by 3 bt/min) 
and end-walk HR is significantly lower (by 15 bt/min) 
than those with HRR≥11 bt/min. These patients also had 
worse spirometry, DLCO, airway wall thickening and 
symptom and exacerbation burden. This is consistent 
with the notion that more severe COPD patients are less 
able to increase HR during 6MWT and, therefore, less able 
to recover by ≥11 bt/min. We suggest that HRR≤10 bt/min 
can be used to identify COPD patients at greater risk for 
worse dyspnoea, quality of life and future exacerbations.
COPD is characterized by poorly-reversible expiratory 
airflow limitation, caused by emphysema and/or airway 
remodeling.31,32 Airway wall thickening and emphysema 
provide independent contributions to expiratory flow lim-
itation and gas exchange impairment in COPD.26 Lower 
FEV1 is associated with both greater airway wall 
thickness33,34 and with emphysema and gas trapping.35,36 
We used CT to assess airway remodeling33 and 
emphysema37 in relation to 6MWT performance and 
HRR. We measured wall area percentage, airway wall 
thickness and Pi10, which collectively reflect wall thicken-
ing across the entire bronchial tree and negatively associ-
ate with FEV1.35 We demonstrated that wall area 
percentage, airway wall thickness and Pi10, but not mea-
sures of emphysema, decreased progressively with 
increasing HRR, and were independently negatively asso-
ciated with HRR≤10 bt/min in smokers with or without 
COPD. As emphysema and impaired DLCO are more 
strongly associated with exercise-induced arterial hypox-
emia, it might be hypothesized that HRR recovery would 
be more impaired in those with greater gas exchange 
abnormalities.38 In accordance with this suggestion, 
DLCO was negatively associated with HRR, but we found 
no relation between HRR and emphysema on CT. In 
addition, although 1515 (30.3%) participants experienced 
at least mild exercise induced arterial desaturation (SpO2 
<92%), this was only very weakly associated with HRR 
(β=0.016, 95% CI 0.005–0.027, r2=0.002) (c.f.39). Our 
results are therefore consistent with a greater autonomic 
disturbance in airway predominant disease rather than in 
emphysema.
Vagal afferent innervation of the respiratory tract is thought 
to be activated in COPD by alterations in airway mechanical 
stimuli, inflammatory and noxious sensory stimuli,16,17 
increasing bronchoconstriction and susceptibility to cough. 
Similarly, sympathetic activity is enhanced in COPD patients, 
and is known to be affected by several mechanisms associated 
with COPD, including: Recurrent hypoxemia; hypercapnia; 
increased intrathoracic pressure alterations; respiratory effort; 
systemic inflammation; pulmonary circulation; and use of 
beta-sympathomimetics resulting in augmented cardiac after-
load. Indeed, anticholinergic bronchodilators reduce HRR 
after exercise in COPD patients,40 and we found greater com-
bination of LABA, LAMA and inhaled corticosteroids use in 
those with abnormal HRR. However, although patients did not 
temporarily abstain from long-acting bronchodilator medica-
tions for this study, the 6MWT was conducted after albuterol 
administration for spirometry assessment in all participants, 
meaning beta-agonist load should have been high in all sub-
jects. In addition, chronic inflammation is associated with 
autonomic dysfunction in middle-aged and elderly subjects 
with no apparent heart disease.41 Taken together, our findings 
support that chronic inflammation and/or an association 
between bronchial and cardiac vagal tone are reflected in an 
association between airway wall thickness and abnormal HRR 
in COPD patients. Therefore, HRR≤10 bt/min cut-off might 
provide a prognostic feature of airway-dominant COPD.42 
Further study is warranted to identify mechanisms involved 
in associations among HRR, parasympathetic nervous activity 
and airway wall thickness in COPD. Indeed, the association 
between HRR and airway abnormalities remains even when 
diagnostic criteria (eg COPD or non-COPD) are considered. 
This suggests that HRR may represent a treatable trait,43 
mediated by an underlying airway and/or autonomic patho-
physiology, that could be a target to improve outcomes agnos-
tic of diagnostic phenotype.
The GOLD ABCD assessment tool20,44 identifies high-
est risk COPD patients using exacerbation frequency ≥2 in 
the previous year, combined with significant dyspnoea 
assessed by CAT ≥10 or mMRC ≥2. GOLD D patients 
have the worst health status and outcomes.20 To our 
knowledge, this is the first study to show that HRR≤10 
bt/min was independently associated with GOLD D COPD 
classification. COPD patients with HRR≤10 bt/min have 
greater risk for symptoms and frequent exacerbations than 
those with HRR≥11 bt/min. We also demonstrated that 
HRR≤10 bt/min was a predictor for future exacerbation 
at 5-year follow-up in 385 COPD patients.
https://doi.org/10.2147/COPD.S311572                                                                                                                                                                                                                               
DovePress                                                                                              
International Journal of Chronic Obstructive Pulmonary Disease 2021:16 2556
Zhao et al                                                                                                                                                             Dovepress
















































































Previous studies have associated HRR≤14 bt/min with 
future exacerbation risk15 or mortality in COPD.7 These 
studies, however, found no association between HRR and 
pulmonary function or symptoms. HRR≤10 bt/min after 
6MWT, on the other hand, identified associations with 
both COPD severity and future exacerbation. This, again, 
supports the notion that HRR≤10 bt/min after 6MWT may 
further inform COPD prognosis.
Our study has several limitations. Firstly, we do not 
have mortality data to assess association with HRR at 
different cut-off values. At the time of writing, only 
a modest fraction of COPDGene participants have been 
followed up at their 10-year visit (phase 3), introducing 
potential for selection bias in our exacerbation outcome 
data. There also remains chance bias due to the multi-
ple outcomes examined. Secondly, common medica-
tions such as β-agonists may alter the HR and HRR 
response to 6MWT. However, the type and amount of 
medication use is a Co-variate of COPD severity; 
therefore, adjusting for medication confounds analyses 
for associations between HRR and COPD severity. We 
also sought to adjust for peak HR in our models. 
Adjustment of peak HR tended to increase the strength 
of association between HRR and some model variables, 
eg the association between HRR and FEV1%pred 
increased from β=0.194 to β=0.318 (P<0.001 for 
both). However, peak HR is used in the calculation of 
HRR, and its inclusion introduced variance of the 
coefficients without major impact on the primary 
study conclusions. For this reason, peak HR was not 
included in the presented models. In addition, exacer-
bations in the previous year are known to be the pri-
mary predictor of subsequent exacerbations. Since we 
did not measure exacerbations prior to our follow-up 
window, we are not able to assess the independence of 
HRR as a predictor of exacerbations at 5-year follow 
up. Finally, patients with HRR≤10 bt/min are also 
included in groups with greater cut-off values (eg, 
≤12–16 bt/min), which introduces bias when attempt-
ing to identify which cut-off value to use. Here we 
chose to report the lowest value, because COPD is 
predisposed to lower end-walk HR values than some 
other patient populations. Although not shown, using 
≤12, ≤14 or ≤16 bt/min as more granular criteria cut- 
off values, did not change the main finding that 
HRR≤10 bt/min was the lowest HRR criterion identify-
ing severe impairments in clinical outcomes.
Conclusions
In conclusion, in this retrospective study we demonstrated 
that HRR≤10 bt/min after 6MWT in COPD was associated 
with: 1) worse lung function and airway wall thickening; 2) 
worse dyspnoea and quality of life; and 3) greater exacer-
bation burden; and was 4) prognostic of future exacerba-
tions. These findings suggest that HRR of ≤10 bt/min may 
be useful as part of a comprehensive longitudinal assess-
ment in COPD patients to determine risk for disease 
severity, symptoms and future exacerbations.
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